《新英格兰医学杂志》发表针对溃疡性结肠炎的首项头对头临床研究,强调了维多珠单抗与阿达木单抗相比的优越性

2019-09-26 不详 MedSci原创

日本武田制药有限公司宣布了VARSITY研究的进一步结果,该研究证明了肠道选择性维多珠单抗(Entyvio)与抗肿瘤坏死因子α(抗TNFα)阿达木单抗(Humira)的优越性,目前该单抗在中度至重度活动溃疡性结肠炎(UC)患者中已经实现临床的主要终点,数据发表在《新英格兰医学杂志》(NEJM)上。在第52周时,维多珠单抗31.3%(n = 120/383)的临床缓解率要好于阿达木单抗的22.5%(

日本武田制药有限公司宣布了VARSITY研究的进一步结果,该研究证明了肠道选择性维多珠单抗(Entyvio)与抗肿瘤坏死因子α(抗TNFα)阿达木单抗(Humira)的优越性,目前该单抗在中度至重度活动溃疡性结肠炎(UC)患者中已经实现临床的主要终点,数据发表在《新英格兰医学杂志》(NEJM)上。在第52周时,维多珠单抗31.3%(n = 120/383)的临床缓解率要好于阿达木单抗的22.5%(n = 87/386)(p = 0.006)。

NEJM上发表的数据显示,在两个未接受TNFα治疗的患者中,与阿达木单抗相比,vedolizumab在52周时的临床缓解百分比均更高(34.2%[n = 104/304] vedolizumab与24.3%[n = 74 / 305]阿达木单抗)。在第14周接受维多珠单抗治疗的患者中有26.6%(n = 102/383)达到临床缓解,而使用阿达木单抗治疗的患者为21.2%(n = 82/386)。维多珠单抗患者的持久临床缓解率为18.3%(n = 70/383)和阿达木单抗为11.9%(n = 46/386)。

维多珠单抗是一种肠选择性、人源化单克隆抗体,设计用于特异性拮抗α4beta7整联蛋白,抑制α4beta7整联蛋白与肠粘膜寻址蛋白细胞粘附分子1(MAdCAM-1)的结合。vedolizumab通过抑制alpha4beta7整联蛋白,限制白细胞浸润肠道组织的能力。

原始出处:

http://www.firstwordpharma.com/node/1669352?tsid=4#axzz60XQoImru

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695111, encodeId=7603169511104, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Nov 02 15:54:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Nov 19 13:54:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748682, encodeId=868f1e48682b9, content=<a href='/topic/show?id=52d15861349' target=_blank style='color:#2F92EE;'>#新英格兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58613, encryptionId=52d15861349, topicName=新英格兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3e36178621, createdName=shalley78, createdTime=Wed Jan 15 05:54:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480124, encodeId=f56c14801246b, content=<a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fec7610558, createdName=ms9476844295372110, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615635, encodeId=87961615635bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=)]
    2019-11-02 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695111, encodeId=7603169511104, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Nov 02 15:54:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Nov 19 13:54:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748682, encodeId=868f1e48682b9, content=<a href='/topic/show?id=52d15861349' target=_blank style='color:#2F92EE;'>#新英格兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58613, encryptionId=52d15861349, topicName=新英格兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3e36178621, createdName=shalley78, createdTime=Wed Jan 15 05:54:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480124, encodeId=f56c14801246b, content=<a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fec7610558, createdName=ms9476844295372110, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615635, encodeId=87961615635bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695111, encodeId=7603169511104, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Nov 02 15:54:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Nov 19 13:54:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748682, encodeId=868f1e48682b9, content=<a href='/topic/show?id=52d15861349' target=_blank style='color:#2F92EE;'>#新英格兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58613, encryptionId=52d15861349, topicName=新英格兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3e36178621, createdName=shalley78, createdTime=Wed Jan 15 05:54:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480124, encodeId=f56c14801246b, content=<a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fec7610558, createdName=ms9476844295372110, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615635, encodeId=87961615635bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695111, encodeId=7603169511104, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Nov 02 15:54:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Nov 19 13:54:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748682, encodeId=868f1e48682b9, content=<a href='/topic/show?id=52d15861349' target=_blank style='color:#2F92EE;'>#新英格兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58613, encryptionId=52d15861349, topicName=新英格兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3e36178621, createdName=shalley78, createdTime=Wed Jan 15 05:54:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480124, encodeId=f56c14801246b, content=<a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fec7610558, createdName=ms9476844295372110, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615635, encodeId=87961615635bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695111, encodeId=7603169511104, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Nov 02 15:54:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Nov 19 13:54:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748682, encodeId=868f1e48682b9, content=<a href='/topic/show?id=52d15861349' target=_blank style='color:#2F92EE;'>#新英格兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58613, encryptionId=52d15861349, topicName=新英格兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3e36178621, createdName=shalley78, createdTime=Wed Jan 15 05:54:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480124, encodeId=f56c14801246b, content=<a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fec7610558, createdName=ms9476844295372110, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615635, encodeId=87961615635bb, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sat Sep 28 02:54:00 CST 2019, time=2019-09-28, status=1, ipAttribution=)]

相关资讯

NEJM:抗肿瘤药心脏毒性十五要点

近期,《新英格兰医学杂志》在线发表了《抗肿瘤药物的心脏毒性》一文,以下是这篇文章的要点,值得心血管医师和肿瘤科医师共同关注。 1 过去20年对肿瘤发生发展的分子机制逐步有了深入的了解,并研发出了很多以肿瘤发病机制为基础的、高选择性的抗肿瘤药物; 2 新的肿瘤靶向治疗药物的广泛应用极大程度地改变了多种肿瘤的自然病程,但是在实施治疗期间或是疗程结束后的心血管并发症如血栓性事件、心肌

中国研究入选《新英格兰医学杂志》评选的2018重要NEJM论文

医学不断向前发展,2018年也不例外。《新英格兰医学杂志》发表的许多文章改变了我们的观点,其中一些文章的坚实证据甚至改变了我们的做法。如果要永远站立在医学最前沿,您有必要了解这些“颠覆性”文章。以下是2018年的一些颠覆性文章。在我们的职业生涯中,过去的很长一段时间我们都在告诉发生过心肌梗死或卒中等主要心血管事件的患者,每日服用约82 mg阿司匹林有助于预防心梗或卒中复发。而且因为我们觉得这一干预

一篇中国学者的《新英格兰医学杂志》文章是怎样炼成的?

这是一篇讲述中国学者如何克服困难, 将原创研究推上世界知名学术舞台的文章。 2018年初,《新英格兰医学杂志》(NEJM)发表了复旦大学附属华山医院、国家老年疾病临床医学研究中心(华山)徐文东团队“健侧颈7移位术治疗中枢损伤后上肢痉挛瘫的临床试验”。 这项研究是一项手术新技术的临床试验,是完全中国原创的全新治疗策略,一经发表便在学术界和患者中引起了巨大反响。该文被NEJM编辑部评